drugset / Trial / NCT00370071

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

NCT00370071

Phase 3 Completed 39 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.

Timeline

Start
2006-11
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1b Protein / enzyme biologic 250 ug Subcutaneous

Indications